Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients

Sohag University

Status

Enrolling

Conditions

Coronary Artery Disease

Premature

Non-Diabetic

Angiographic Profiling

Triglycerides Glucose Index

Treatments

Other: Coronary Angiographic Assessment

Study type

Observational

Funder types

Other

Identifiers

NCT07154186

Soh-Med-25-5-5PD

Details and patient eligibility

About

This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).

Full description

Premature coronary artery disease (CAD), defined as CAD occurring before the age of 55 in men and 65 in women, has emerged as a growing health concern worldwide.

Insulin resistance and associated metabolic alterations are strongly implicated in premature atherosclerosis. Even in non-diabetic individuals, subclinical insulin resistance promotes endothelial dysfunction, oxidative stress, and low-grade inflammation, leading to early vascular damage.

The triglyceride-glucose (TyG) index, calculated using fasting glucose and triglyceride levels, has emerged as a cost-effective surrogate marker for insulin resistance.

Enrollment

180 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years old.
Both sexes.
Non-diabetic patients [no history of diabetes, hemoglobin A1C (HbA1C) < 6.5%, fasting glucose < 126 mg/dL].
Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.

Exclusion criteria

Known diabetes mellitus (type 1 or type 2).
Previous history of coronary revascularization.
Severe hepatic or renal dysfunction [alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)< 30 mL/min/1.73 m²].
Malignant disease, autoimmune disease, or systemic inflammatory disorders.
Current use of triglyceride-lowering medications.